Tandem Mobi Now Compatible with Android Smartphones

Key Takeaways

• Android compatibility adds millions of potential users
• FDA cleared app ensures regulatory compliance and safety
• Control‑IQ+ maintains 79% overall time‑in‑range
• Wearable pump offers discreet, on‑body use options
• App available on Google Play for Pixel and Galaxy models

Summary

Tandem Diabetes Care announced that its Tandem Mobi insulin pump is now compatible with Android smartphones in the United States via a newly released mobile app. The Android version received FDA clearance in November 2025 and entered a limited rollout in December 2025. Tandem Mobi leverages the Control‑IQ+ predictive algorithm, delivering 79% overall time‑in‑range and 90% overnight time‑in‑range. The expansion follows an iPhone‑only launch earlier in 2024, broadening the device’s user base.

Pulse Analysis

The convergence of mobile technology and diabetes management has accelerated in recent years, with patients demanding seamless data integration and real‑time control. By extending Tandem Mobi to Android, the company taps into a market segment that represents roughly 70% of global smartphone users, addressing a longstanding gap in its ecosystem. This move not only satisfies consumer expectations for cross‑platform flexibility but also positions Tandem to capture a larger share of the growing automated insulin delivery market, where convenience and connectivity are key differentiators.

Tandem Mobi’s compact form factor, combined with the Control‑IQ+ algorithm, delivers clinically significant outcomes—79% time‑in‑range overall and 90% overnight—without sacrificing wearability. Users can attach the pump to the body with an adhesive sleeve, clip it to clothing, or tuck it into a pocket, offering discretion that traditional pumps lack. The Android app mirrors the iOS experience, providing secure pairing, remote monitoring, and direct communication with the Tandem Source platform, which empowers clinicians with richer data for treatment adjustments.

From a strategic perspective, the Android rollout strengthens Tandem’s competitive moat against rivals such as Medtronic and Abbott, whose devices remain tied to specific operating systems. The broader device compatibility is likely to boost subscription revenue for the Tandem Source cloud service and stimulate ancillary sales of accessories and continuous glucose monitors. As the diabetes tech landscape evolves, manufacturers that prioritize platform agnosticism will capture the most engaged user base, and Tandem’s timely expansion positions it to lead the next wave of connected‑care innovation.